Intellia Therapeutics (NTLA) Scheduled to Post Quarterly Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA) will be announcing its earnings results before the market opens on Thursday, October 31st. Analysts expect the company to announce earnings of ($0.61) per share for the quarter.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, August 1st. The company reported ($0.56) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.61) by $0.05. Intellia Therapeutics had a negative return on equity of 33.03% and a negative net margin of 242.65%. The firm had revenue of $11.10 million during the quarter, compared to analyst estimates of $7.15 million. During the same period in the previous year, the company earned ($0.52) EPS. The company’s revenue for the quarter was up 44.2% on a year-over-year basis. On average, analysts expect Intellia Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

NTLA opened at $11.05 on Friday. The business has a 50 day moving average price of $12.75 and a 200 day moving average price of $15.23. Intellia Therapeutics has a twelve month low of $10.26 and a twelve month high of $20.42. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.99 and a current ratio of 7.99. The firm has a market cap of $545.45 million, a P/E ratio of -5.58 and a beta of 2.70.

Several equities research analysts recently weighed in on NTLA shares. Robert W. Baird started coverage on Intellia Therapeutics in a report on Monday, July 8th. They issued an “outperform” rating and a $23.00 target price for the company. ValuEngine upgraded Intellia Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. Zacks Investment Research downgraded Intellia Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 8th. Chardan Capital set a $57.50 price target on Intellia Therapeutics and gave the stock a “buy” rating in a research report on Friday, September 27th. Finally, BidaskClub downgraded Intellia Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, October 11th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $25.56.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.

See Also: Overbought

Earnings History for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.